x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0243249
| Product Information | |
|---|---|
| CAS No. | 2411088-26-9 |
| Formula | C24H29Cl2N5O2 |
| Molecular Weight | 490.43 |
| SMILES | CN(C1=O)C(C(N(C2CCCC2)[C@@H]1CC3CCCC3)=N4)=CN=C4NC5=CC(Cl)=C(C(Cl)=C5)O |
| Target | PI5P4K |
| Product Description | CC260 is a selective PI5P4Kα and PI5P4Kβ inhibitor with Kis of 40 nM and 30 nM, respectively. CC260 does not inhibit or weakly inhibits other protein kinases, such as Plk1 and RSK2. CC260 can be used for cell energy metabolism, diabetes and cancer research. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Color | Off-white to gray |
| Purity | 99.21% |
| Shipping | Room temperature in the continental U.S. Other areas may vary. |
| Storage | Powder: -20°C, 3 years; 4°C, 2 years In solvent: -80°C, 6 months; -20°C, 1 month |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
